Evaluation of Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction Treated With Warfarin or Reduced Dose Rivaroxaban

Trial Profile

Evaluation of Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction Treated With Warfarin or Reduced Dose Rivaroxaban

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Acronyms CALLIPER
  • Sponsors Bayer
  • Most Recent Events

    • 04 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 06 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top